LONDON (Alliance News) - ANGLE PLC said Monday that further "highly encouraging" results supporting the use of its Parsortix system in the detection of ovarian cancer has been published by the Medical University of Vienna.
The University has published results from further work with the system at the European Cancer Congress European Society for Medical Oncology in Vienna.
The company said the work further substantiates the value of its system and its application in detecting ovarian cancer. Parsortix works by separating and harvesting cells from a patients blood that can be used to identify cancer.
"Detection of ovarian cancer is ANGLE's first clinical application for our Parsortix system. The continued strong results from Medical University of Vienna are impressive," said Founder and Chief Executive Andrew Newland in a statement.
Shares in ANGLE were up 4.6% at 84.20 pence.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Angle (AGL)